Skip to main content
20th International Myeloma Workshop Main banner
Back

    Sergio Giralt, MD

    Professor
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States

    Sergio Giralt received his medical degree from Universidad Central de Venezuela. He completed his residency at Good Samaritan Hospital and his fellowship at The University of Texas MD Anderson Cancer Center. In addition to his positions at Memorial Sloan Kettering Cancer Center, Dr. Giralt is Professor of Medicine at Weill Cornell Medical College and the Melvin Berlin Family Chair in Myeloma Research.
    Dr. Giralt is an active member of several professional societies, including the American Society of Hematology, the American Society of Clinical Oncology, the North American Society of Transplant and Cellular Therapy (ASTCT) and the International Society of Hematotherapy and Graft Engineering, He previously served as chairperson on the executive board of the Center for International Blood and Marrow Transplant Research and the steering committee of the Blood and Marrow Transplant Clinical Trials Network, and he is past president of ASBMT.
    A board-certified hematologist/oncologist whose clinical practice and research focus on stem cell transplantation for patients with blood disorders, Dr. Giralt with his colleagues pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers. He has worked extensively with other colleagues to reduce symptom burden post transplant and has made major contributions to this field. Currently, Dr. Giralt was a founding membe of the BMT CTN Myeloma Intergroup Steering Committee that has helped developed the research agenda for myeloma and transplant in the United States since 2010. He has published and presented extensively on a variety of topics in transplant and cellular therapies. Additionally, Dr. Giralt has served as the principal investigator for a number of clinical trials that examine new treatment approaches for multiple myeloma and other blood cancers that aim to reduce symptom burden and improve treatment tolerability.

    Presentation(s):